Adderall Shortage Persists Into 2026 — Modest DEA Quota Increase Offers Limited Relief
The ongoing Adderall shortage in the U.S. has persisted since late 2022, causing inconsistent access for patients. Although the DEA increased production limits for stimulants, manufacturing delays and supply chain issues complicate availability. Patients are urged to plan refills early while advocates continue to push for systemic changes to address this crisis.